But it will be up to doctors whether to use the combo in Darzalex-exposed patients.
ApexOnco Front Page
Recent articles
Persevera is a bust, but Roche hasn’t given up on the front line.
Jazz’s Chimerix buy faces its big test.
The first data are dribbled out, but cross-trial comparisons look uninspiring.
More data from onvansertib's phase 2 study fail to convince.
NT-125 is discontinued, while two key Datroway readouts are delayed.
A Pfizer cast-off could become the company's first marketed drug.
Meanwhile, investors await key clinical data.
